Client Announcement: Congrats Fina Biosolutions!

Yesterday an exciting milestone for our client Fina Biosolutions was announced.  

SK Bioscience has made public a $3M investment in Fina Biosolutions (FinaBio), a biotechnology company specializing in next-generation conjugate vaccine technology. This investment will support FinaBio's groundbreaking work in making affordable vaccines accessible globally.

Over the past few years, Omnium Global has had the privilege of supporting along the journey to reaching this significant milestone. Working closely with Andrew Lees, Founder and CEO of FinaBio, we assisted in structuring the deal and negotiating terms to help secure SK bioscience as FinaBio’s first strategic investor.

This partnership will accelerate the development of critical conjugate vaccines, advancing public health initiatives worldwide. It’s been an incredible journey to collaborate with FinaBio and play a role in bringing their vision to life. 💉🌍

Read the full press release on SK Bioscience's Website: https://www.skbioscience.com/en/news/news_01_01?mode=view&id=276&

ABOUT FINA BIOSOLUTIONS LLC:

Fina Biosolutions LLC is a conjugation CRO/R&D company founded by Andrew Lees, PhD. Dr. Lees is the developer of the CDAP conjugation method used by GSK, Pfizer, The Serum Institute of India, and others in their polysaccharide conjugate vaccines. FinaBio has developed FinaXpressTM, an E. coli expression platform for high-titer production of soluble, cytoplasmic disulfide-bonded proteins. The FinaXpressTM platform allows us to produce our GMP-grade CRM197 carrier protein and to offer strain development services for difficult-to-express proteins. The company has built on its conjugation expertise and now manufactures dextran-based reagents, which are used for flow cytometry, bead modification, and a myriad of other applications.

Learn more about their products and services at: https://finabio.net